Incyte’s Q2 Financial Outlook: Will Strong Sales Fuel a Breakthrough-Heavy Drug Portfolio?

Incyte (INCY) is set to announce its second-quarter financial results on July 28, 2026.

The company’s primary therapeutic focus areas encompass Haematology, Oncology, Inflammation, and Autoimmunity.

Beyond the sales trajectories of Polycythemia vera treatment Jakafi and Atopic dermatitis treatment Opzelura, stakeholders will also focus on newer oncology products such as Zynyz and several late-stage clinical data releases anticipated later this year.

First Quarter Of 2026

In Q1 2026, Incyte reported net income of $303.33 million, or $1.47 per share, compared to $158.20 million, or $0.80 per share, in the prior year. The company’s total revenue reached $1.27 billion, up from $1.05 billion a year ago.

Jakafi sales for Polycythemia vera (PV) grew 7% to $757.76 million from $709.41 million. Opzelura sales for atopic dermatitis (AD) and vitiligo rose 20% to $143.02 million from $118.71 million. Iclusig sales for Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) increased 20% to $35.46 million from $29.54 million a year ago.

Pemazyre revenue for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion climbed 22% to $22.54 million from $18.44 million. Minjuvi/Monjuvi revenue for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) surged 67% to $49.23 million from $29.55 million a year ago.

Niktimvo revenue in chronic graft versus host disease (GVHD) improved 305% to $55.09 million from $13.61 million. Zynyz sales for squamous cell carcinoma of the anal canal (SCAC) skyrocketed 1,276% to $41.39 million from $3.01 million a year ago.

As of March 31, 2026, cash, cash equivalents, and marketable securities totalled $4 billion.

Second Quarter 2025

In Q2 2025, Incyte swung to a net income of $404.99 million from a loss of $444.60 million, or a $2.04 per-share loss, in the year-ago period.

On an adjusted basis, net income was $311.93 million, or $1.57 per share, compared to a loss of $396.13 million, or $1.82 per share, in the prior year. The company recorded total revenue of $1.22 billion, up from $1.04 billion a year ago.

In Q2 2025, Jakafi revenue grew 8% to $763.78 million from $705.97 million. Opzelura sales rose 35% to $164.49 million from $121.70 million. Iclusig sales increased 22% to $32.73 million from $26.86 million. Pemazyre sales improved 9% to $22.19 million from $20.27 million. Minjuvi/Monjuvi sales were $31.13 million, nearly flat with $31.12 million in the prior year.

Niktimvo generated $36.15 million in revenue, and Zynyz sales improved 1,270% to $8.92 million from $0.651 million in the year-ago period.

2026 Near-term Milestones

In April 2026, the company updated the following milestones:

– Topline data from the Phase 2 trial evaluating Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic GVHD is anticipated in the second half of 2026.

– Topline results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026.

– Data from the Phase 3 studies (STOP-PN1 and STOP-PN2) evaluating povorcitinib in patients with moderate-to-severe prurigo nodularis (PN) are anticipated in the fourth quarter of 2026.

– Topline data from the Phase 2 proof-of-concept trial for povorcitinib in asthma are anticipated in the second half of 2026.

– Data from the Phase 1 trial evaluating INCB160058 in patients with myeloproliferative neoplasms (MPNs) with a JAK2V617F mutation are anticipated in the second half of 2026.

– Additional data from the ongoing Phase 1 trial evaluating INCB161734 in combination with standard-of-care chemotherapy as a first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) are anticipated in the second half of 2026.

– Further data from the ongoing Phase 1 study evaluating INCA33890 in combination with bevacizumab and/or chemotherapy in patients with solid tumors is expected in the second half of 2026.

2026 Guidance

Looking ahead to full-year 2026, total net sales are projected to be in the range of $4,770 million to $4,940 million. Jakafi net sales are expected to fall between $3,220 million and $3,270 million, while Opzelura net sales are forecasted in the range of $750 million to $790 million.

Haematology and Oncology portfolio sales are anticipated to be between $800 million and $880 million.

Stock Performance

INCY has traded between $69.69 and $119.60 over the last year. The stock closed Friday’s trade (July 27, 2026) at $117.67, up 0.84%.

Source link